Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

Authors

Jorge E Cortes, University of Texas M.D. Anderson Cancer Center
Mark A Schroeder, Washington University School of Medicine in St. Louis
et al

Journal

American Journal of Hematology

Publication Date

11-1-2018

Volume

93

Issue

11

First Page

1301

Last Page

1310

Document Type

Open Access Publication

DOI

10.1002/ajh.25238

Rights and Permissions

Cortes, JE, Douglas Smith, B, Wang, ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. Am J Hematol. 2018; 93 1301– 1310. https://doi.org/10.1002/ajh.25238 © 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Recommended Citation

Cortes, Jorge E; Schroeder, Mark A; and et al, "Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results." American Journal of Hematology. 93, 11. 1301 - 1310. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8382